IO Biotech Q2 2024 GAAP EPS $(0.31) Beats $(0.35) Estimate, Cash Balance Of $100.7M Expected To Support Operations Into The Q4 Of 2025
Portfolio Pulse from Benzinga Newsdesk
IO Biotech reported a Q2 2024 GAAP EPS of $(0.31), beating the estimate of $(0.35). The company has a cash balance of $100.7 million, which is expected to support operations into Q4 2025.
August 13, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IO Biotech reported a better-than-expected Q2 2024 GAAP EPS of $(0.31) compared to the estimated $(0.35). The company's cash balance of $100.7 million is expected to support operations into Q4 2025.
The better-than-expected earnings per share (EPS) and strong cash position are positive indicators for IO Biotech. Beating EPS estimates typically boosts investor confidence and can lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100